P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

被引：40

作者：

Coronado, PJ ^{[1
]}

Vidart, JA

Lopez-asenjo, JA

Fasero, M

Furio-bacete, V

Magrina, J

Escudero, M

机构：

[1] Hosp Clin San Carlos, Dept Obstet & Gynecol, Madrid, Spain

[2] Hosp Clin San Carlos, Dept Pathol, Madrid, Spain

[3] Mayo Clin, Dept Gynecol Surg, Scottsdale, AZ USA

来源：

EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2001年 / 98卷 / 01期

关键词：

p53; HER-2/neu; endometrial cancer; prognostic factors; survival; immunohistochemistry;

D O I：

10.1016/S0301-2115(00)00562-5

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Objective: to investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer. Study Design: p53 and HER2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial. cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used. Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P < 0.001) and HER-2/neu (P = 0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P < 0.001), FIGO stage (P < 0.001), differentiation (P = 0.013), non-endometrioid subtypes (P < 0.001) and p53 overexpression (P < 0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P <less than> 0.001). Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：103 / 108

页数：6

共 42 条

[1]

AMBROS RA, 1994, CANCER, V73, P1686, DOI 10.1002/1097-0142(19940315)73:6<1686::AID-CNCR2820730622>3.0.CO

[2]

2-W

[3] THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].

BARGMANN, CI ;

HUNG, MC ;

WEINBERG, RA .

NATURE, 1986, 319 (6050) :226-230

[4] OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].

BERCHUCK, A ;

RODRIGUEZ, G ;

KINNEY, RB ;

SOPER, JT ;

DODGE, RK ;

CLARKEPEARSON, DL ;

BAST, RC .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (01) :15-21

[5]

BIGSBY RM, 1992, OBSTET GYNECOL, V79, P95

[6]

BRUKE TW, 1996, OBSTET GYNECOL CLIN, V23, P411

[7] Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma [J].

Coppola, D ;

Fu, L ;

Nicosia, SV ;

Kounelis, S ;

Jones, M .

HUMAN PATHOLOGY, 1998, 29 (05) :455-462

[8]

COX DR, 1972, J R STAT SOC B, V34, P187

[9] RISK-FACTORS AND RECURRENT PATTERNS IN STAGE-I ENDOMETRIAL CANCER [J].

DISAIA, PJ ;

CREASMAN, WT ;

BORONOW, RC ;

BLESSING, JA .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 151 (08) :1009-1015

[10]

ENOMOTO T, 1993, CANCER RES, V53, P1883

← 1 2 3 4 5 →